Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 19/20 | 0.61 |
| ▸ | RARB | P10826 | 7/20 | 0.56 |
| ▸ | RXRB | P28702 | 6/20 | 0.56 |
| ▸ | RARG | P13631 | 6/20 | 0.56 |
| ▸ | RXRG | P48443 | 6/20 | 0.56 |
| ▸ | RARA | P10276 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080909 | 0.86 | RXRA (0.62) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL7083828 | 0.84 | RXRA (0.53) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL3633427 | 0.84 | RXRA (0.65) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL7800113 | 0.82 | RXRA (0.58) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL7083909 | 0.81 | RXRA (0.56) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL7080041 | 0.81 | RXRA (0.56) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL29374183 | 0.80 | RXRA (0.63) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL112943 | 0.80 | RXRA (0.63) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL7220989 | 0.79 | RXRA (0.54) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL7085844 | 0.78 | RXRA (0.60) | RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191145-A1 | Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-09 | — | — | US | claimed |
| EP-0905118-B1 | Unsaturated 6-tert-butyl-1,1-dimethylindane derivates substituted in the 4-position and their use in human and veterinary medicine as well as in cosmetics | GALDERMA RES & DEV (FR) | 2001-08-16 | — | — | EP | claimed |
| US-6180674-B1 | THERAPY FOR SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2001-01-30 | — | — | US | claimed |
| EP-0905118-A1 | Unsaturated 6-tert-butyl-1,1-dimethylindane derivates substituted in the 4-position and their use in human and veterinary medicine as well as in cosmetics | Galderma Research & Development, S.N.C. (FR) | 1999-03-31 | — | — | EP | claimed |
| US-6642273-B2 | Dermatology, vision defects, cardiovascular disorders, antiinflammatory | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-11-04 | — | — | US | disclosed |
| US-20030191145-A1 | Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-09 | — | — | US | disclosed |
| US-6534545-B1 | Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-03-18 | — | — | US | disclosed |
| EP-0905118-B1 | Unsaturated 6-tert-butyl-1,1-dimethylindane derivates substituted in the 4-position and their use in human and veterinary medicine as well as in cosmetics | GALDERMA RES & DEV (FR) | 2001-08-16 | — | — | EP | disclosed |
| US-6180674-B1 | THERAPY FOR SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2001-01-30 | — | — | US | disclosed |
| EP-0905118-A1 | Unsaturated 6-tert-butyl-1,1-dimethylindane derivates substituted in the 4-position and their use in human and veterinary medicine as well as in cosmetics | Galderma Research & Development, S.N.C. (FR) | 1999-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191145-A1 | Unsaturated derivatives at the 4-position of 6-tert-butyl-1,1-dimethylindane and their use in human and veterinary medicine and in cosmetics | REL, DERL1, TLR7 | RXRA 30/4885RARB 119/4885RXRB 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.